ARTIVA BIOTHERAPEUTICS

Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies. Our lead product candidate, AlloNK®, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs). AlloNK is currently in clinical trials for treatment of systemic lupus erythematosus (SLE) in patients with or without lupus nephritis and in an investigator-initiated basket trial in multiple autoimmune indications. In addition, AlloNK is being evaluated for the treatment of non-Hodgkin lymphoma, as well as in combination with Affimed's innate cell engager acimtamig for the treatment of patients with relapsed/refractory CD30-positive lymphomas... Artiva Biotherapeutics is a cell therapy company with the ability to produce highly scaled, off-the-shelf, allogeneic NK cell therapies... We are a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based..

Also known as: Artiva Biotherapeutics, Inc.

Primary location: San Diego United States